[go: up one dir, main page]

DK3272861T3 - Alpha-galactosidase-sammensætninger - Google Patents

Alpha-galactosidase-sammensætninger Download PDF

Info

Publication number
DK3272861T3
DK3272861T3 DK17164713.4T DK17164713T DK3272861T3 DK 3272861 T3 DK3272861 T3 DK 3272861T3 DK 17164713 T DK17164713 T DK 17164713T DK 3272861 T3 DK3272861 T3 DK 3272861T3
Authority
DK
Denmark
Prior art keywords
galactosidase
formations
alpha
Prior art date
Application number
DK17164713.4T
Other languages
English (en)
Inventor
Avidor Shulman
Uri Hanania
Tali Kizhner
Yoseph Shaaltiel
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2011/000209 external-priority patent/WO2011107990A1/en
Application filed by Protalix Ltd filed Critical Protalix Ltd
Application granted granted Critical
Publication of DK3272861T3 publication Critical patent/DK3272861T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
DK17164713.4T 2011-01-20 2011-09-07 Alpha-galactosidase-sammensætninger DK3272861T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161434503P 2011-01-20 2011-01-20
US201161434499P 2011-01-20 2011-01-20
PCT/IL2011/000209 WO2011107990A1 (en) 2010-03-02 2011-03-02 Stabilized alpha-galactosidase and uses thereof
EP11767776.5A EP2665814B1 (en) 2011-01-20 2011-09-07 Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells

Publications (1)

Publication Number Publication Date
DK3272861T3 true DK3272861T3 (da) 2020-03-23

Family

ID=44786043

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17164713.4T DK3272861T3 (da) 2011-01-20 2011-09-07 Alpha-galactosidase-sammensætninger
DK11767776.5T DK2665814T3 (da) 2011-01-20 2011-09-07 Nukleinsyrekonstruktion til ekspression af alpha-galactosidase i planter og planteceller

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11767776.5T DK2665814T3 (da) 2011-01-20 2011-09-07 Nukleinsyrekonstruktion til ekspression af alpha-galactosidase i planter og planteceller

Country Status (19)

Country Link
US (1) US9732333B2 (da)
EP (2) EP3272861B1 (da)
JP (1) JP5913372B2 (da)
KR (1) KR101883803B1 (da)
CN (1) CN103443270B (da)
AU (1) AU2011356137A1 (da)
BR (1) BR112013018516B1 (da)
CA (1) CA2824791A1 (da)
CY (1) CY1122794T1 (da)
DK (2) DK3272861T3 (da)
ES (1) ES2774190T3 (da)
IL (1) IL227552B (da)
LT (2) LT3272861T (da)
PL (1) PL3272861T3 (da)
PT (1) PT3272861T (da)
RS (1) RS60129B1 (da)
SI (1) SI3272861T1 (da)
SM (1) SMT202000201T1 (da)
WO (1) WO2012098537A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0815324A2 (pt) 2007-08-20 2015-07-14 Protalix Ltd "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
ES2774190T3 (es) 2011-01-20 2020-07-17 Protalix Ltd Composiciones de alfa-galactosidasa
EP2964669B1 (en) * 2013-03-06 2018-09-12 Protalix Ltd. Use of plant cells expressing a tnfalpha polypeptide inhibitor in therapy
BR112015021708A2 (pt) * 2013-03-06 2017-08-29 Protalix Ltd Inibidor de polipetídeo do tnfa, polinucleotídeo isolado, estrutura de expressão de ácido nucleico, célula de planta, composição farmacêutica e método de produção de um inibidor de polipeptídeo do tnfa
TW202332774A (zh) * 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
EP3271453B1 (en) 2015-03-17 2021-09-08 eleva GmbH Glycosylated lysosomal proteins, method of production and uses
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US12194079B2 (en) * 2017-01-05 2025-01-14 Protalix Ltd. Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase
IL257269A (en) * 2018-01-31 2018-04-09 Olender Tsviya Signaling is directed to the endoplasmic reticulum
KR102209198B1 (ko) * 2019-04-02 2021-02-02 주식회사 바이오앱 식물에서의 발현이 최적화된 재조합 이리신 유전자 및 이를 이용한 재조합 이리신 단백질의 생산 방법
KR102213745B1 (ko) 2019-04-16 2021-02-09 주식회사 바이오앱 돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법
WO2020256372A1 (ko) 2019-06-17 2020-12-24 주식회사 바이오앱 아프리카 돼지열병의 진단을 위한 항원 생산용 재조합 벡터 및 이의 용도
WO2023027402A1 (ko) 2021-08-27 2023-03-02 주식회사 바이오앱 아프리카 돼지열병 바이러스 유래 항원 단백질을 포함하는 아프리카 돼지열병의 예방용 백신
KR102726138B1 (ko) 2023-10-17 2024-11-14 대한민국 백시니아 바이러스 재조합 a33r 단백질 및 이를 포함하는 오르소폭스바이러스 항체 진단 키트

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
CA1192510A (en) 1981-05-27 1985-08-27 Lawrence E. Pelcher Rna plant virus vector or portion thereof, a method of construction thereof, and a method of producing a gene derived product therefrom
JPS6054684A (ja) 1983-09-05 1985-03-29 Teijin Ltd 新規ｄνａ及びハイブリツドｄνａ
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
CA1288073C (en) 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
GB8608850D0 (en) 1986-04-11 1986-05-14 Diatech Ltd Packaging system
JPS6314693A (ja) 1986-07-04 1988-01-21 Sumitomo Chem Co Ltd 植物ウイルスｒｎａベクタ−
ES2060646T3 (es) 1987-02-09 1994-12-01 Lubrizol Genetics Inc Virus rna hibrido.
US5316931A (en) 1988-02-26 1994-05-31 Biosource Genetics Corp. Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes
US6846968B1 (en) 1988-02-26 2005-01-25 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
US5693507A (en) 1988-09-26 1997-12-02 Auburn University Genetic engineering of plant chloroplasts
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5936035A (en) 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
US5614587A (en) 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DE4009630C2 (de) 1990-03-26 1995-09-28 Reinhard Prof Dr Dr Brossmer CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
UA48104C2 (uk) 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
WO1993018148A2 (en) 1992-03-12 1993-09-16 Wisnieski Bernadine J Tumor necrosis factor with modified channel activity
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO1995001994A1 (en) 1993-07-09 1995-01-19 Synergen, Inc. Recombinant ctla4 polypeptides and methods for making the same
US6329191B1 (en) 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5994086A (en) 1994-03-30 1999-11-30 North Shore University Hospital Method for assessing infertility by binding of mannose to sperm cells
AU4772596A (en) 1995-01-30 1996-08-21 New York Blood Center, Inc., The Recombinant alpha-galactosidase enzyme
US5929304A (en) 1995-09-14 1999-07-27 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
IL155588A0 (en) * 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL119310A (en) 1996-09-26 1999-07-14 Metabogal Ltd Cell/tissue culturing device and method
US20010008766A1 (en) 1998-03-17 2001-07-19 Sylvia Daunert Quantitative binding assays using green fluorescent protein as a label
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
AU7645700A (en) 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
US20070172449A1 (en) 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7244823B2 (en) 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7687461B2 (en) 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
HUP0401300A3 (en) 2001-01-18 2005-06-28 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
AU2002340562B2 (en) 2001-10-22 2008-10-23 Merck Serono Sa Compositions of FSH with high sialylation degree and their use for the preparation of medicaments
KR20050044857A (ko) 2001-11-16 2005-05-13 파멕사 에이/에스 무차별 ｔ 세포 에피토프 삽입물을 갖는 멀티머 단백질의면역원성 모방체
JP5570677B2 (ja) 2002-04-25 2014-08-13 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド α−ガラクトシダーゼＡ欠損症の治療
CA2427190A1 (en) * 2002-04-30 2003-10-30 Alberta Research Council Inc. Production of recombinant epidermal growth factor in plants
AU2003235988A1 (en) 2002-05-15 2003-12-02 Agricultural Research Organization, The Volcani Center Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
EP1613264A4 (en) 2003-04-16 2007-08-15 Yeda Res & Dev MEDICAMENT FOR THE TREATMENT OF GAUCHER DISEASE AND METHOD FOR IDENTIFYING IT
US7951557B2 (en) * 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
GB2402677A (en) 2003-05-06 2004-12-15 Sirus Pharmaceuticals Ltd Biodegradable polymer
CN101027388A (zh) 2003-06-12 2007-08-29 建新公司 具有增强活性的修饰的人酸性神经磷脂酶及其制备方法
JP2005043317A (ja) 2003-07-25 2005-02-17 Olympus Corp 糖鎖と生体分子との反応を検出する方法
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20070275007A1 (en) 2003-11-05 2007-11-29 The Government Of The United States Of America, Represented By The Secretary Of Health And Human S Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer
US20080015142A1 (en) 2003-12-03 2008-01-17 Defrees Shawn Glycopegylated Follicle Stimulating Hormone
WO2005077093A2 (en) 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
WO2006093524A2 (en) 2004-07-16 2006-09-08 The General Hospital Corporation Antigen-carbohydrate conjugates
WO2006108052A2 (en) 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
BRPI0616012A2 (pt) 2005-07-18 2011-05-31 Protalix Ltd administração via mucosa ou intestino de macromoléculas biologicamente ativas
KR20070065157A (ko) 2005-12-19 2007-06-22 이수근 고객맞춤형 투자자산 관리기능을 갖는 인터넷뱅킹 시스템및 방법
EP3299033A1 (en) 2006-07-25 2018-03-28 Lipoxen Technologies Limited N-terminal polysialylation
WO2008075957A1 (en) 2006-12-21 2008-06-26 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
PT2457919T (pt) 2007-01-18 2019-09-20 Genzyme Corp Oligossacáridos compreendendo um grupo amino-oxi e os seus conjugados
EP1955712A1 (en) 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
BRPI0810343B1 (pt) 2007-05-07 2021-03-30 Protalix Ltd Dispositivo descartável para o cultivo e colheita de tecidos vegetais e/ou células, método de cultivo e colheita de um tecido vegetal e/ou células vegetais em um volume maior do que 400 litros e sistema de cultivo da célula vegetal
EP2164863A4 (en) 2007-06-15 2010-07-28 Univ Arkansas METHOD FOR THE ADMINISTRATION OF MOLECULES IN CELLS USING A RICIN SUB-UNIT AND RELATED COMPOSITIONS THEREOF
BRPI0815324A2 (pt) 2007-08-20 2015-07-14 Protalix Ltd "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"
WO2010004568A1 (en) 2008-07-10 2010-01-14 Given Imaging Ltd. Device, method and kit for in vivo detection of a biomarker
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
US20120230974A1 (en) 2009-11-17 2012-09-13 Protalix Ltd Alkaline alpha galactosidase for the treatment of fabry disease
BR112012022029B1 (pt) * 2010-03-02 2022-10-11 Protalix Ltd Estrutura de proteina multimérica, seu uso e processo para preparação da estrutura de proteína multimérica
WO2011107991A1 (en) 2010-03-02 2011-09-09 Protalix Ltd. Glucocerebrosidase multimers and uses thereof
ES2774190T3 (es) 2011-01-20 2020-07-17 Protalix Ltd Composiciones de alfa-galactosidasa

Also Published As

Publication number Publication date
CN103443270B (zh) 2017-06-06
CA2824791A1 (en) 2012-07-26
JP5913372B2 (ja) 2016-04-27
ES2774190T3 (es) 2020-07-17
EP3272861A1 (en) 2018-01-24
PL3272861T3 (pl) 2020-07-13
BR112013018516B1 (pt) 2023-11-07
SMT202000201T1 (it) 2020-05-08
PT3272861T (pt) 2020-03-26
EP2665814B1 (en) 2017-05-17
IL227552B (en) 2018-05-31
WO2012098537A8 (en) 2013-09-12
IL227552A0 (en) 2013-09-30
KR20140015330A (ko) 2014-02-06
DK2665814T3 (da) 2017-09-11
KR101883803B1 (ko) 2018-07-31
RS60129B1 (sr) 2020-05-29
US9732333B2 (en) 2017-08-15
LTPA2023531I1 (da) 2023-11-27
CN103443270A (zh) 2013-12-11
JP2014506450A (ja) 2014-03-17
EP2665814A1 (en) 2013-11-27
CY1122794T1 (el) 2021-05-05
AU2011356137A1 (en) 2013-08-15
LTC3272861I2 (da) 2025-09-10
SI3272861T1 (sl) 2020-06-30
BR112013018516A2 (pt) 2019-05-21
WO2012098537A1 (en) 2012-07-26
LT3272861T (lt) 2020-03-25
EP3272861B1 (en) 2019-12-18
US20130295065A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
EP2780065A4 (en) NASAL MASK SYSTEM
DK2769050T3 (da) Propsensor
DE102011100082A8 (de) Traygreifvorrichtung
EP2752374A4 (en) gooseneck
BR112014000879A2 (pt) deflegmador
EP2795884A4 (en) Audio conferencing
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
CO6960543A2 (es) 2-tiopirimidinonas
EP2701512A4 (en) Aldosterone synthase inhibitors
EP2768739A4 (en) EYEWASH FLUID CONTAINER
EP2786752A4 (en) Ropinirole-containing adhesive patch
EP2723481A4 (en) FLOW COMPENSATOR
DK3141251T3 (da) Koloskopi - forberedelse
EP2708561A4 (en) BIO-PIN
EP2762923A4 (en) RADIATION MEASURING DEVICE
EP2738148A4 (en) RECIPROCAL LOCKING BLOCK
DE112011104936A5 (de) Stanzstauchniet
EP2760803A4 (en) Geopolymer product
EP2771685A4 (en) BIOMARKERS OF CANCER
DE112012000958A5 (de) Handsäge
EP2788163A4 (en) POST-MOLDING SYSTEM
EP2729467A4 (en) CRYPTATE COMPOUNDS
EP2698098A4 (en) campimeter
DK2476953T3 (da) Fluidbedkedel